Skip to main content

AMPLITUDE

A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease

medical-cross
Chronic kidney disease, Nephropathy, Proteinuria
user
All genders
person-wave 18-65
world
Recruiting now
More information  

Overview

Principal Investigator: Daniel Weiner, MD, MS

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

Study details

Inclusion Criteria
  • Age 18-65
  • Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex-designated investigational clinical study assay.
Exclusion Criteria
  • History of organ / bone marrow transplantation
  • Diagnosis of Diabetes Mellitus
  • History of human immunodeficiency virus (HIV), hepatitis B (HBV) infection, or hepatitis C (HCV) infection.
Study Requirements

This study will last approximately 2 years. Patients will have visits approximateley every 4 weeks, blood drawn, ECGs taken, and vitals taken. Home health visits available.

If you aren't sure if you qualify, please call us and we will help determine your eligibility. 

Jump back to top